FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma - Wikidata - awgldk - TriplyDB

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

http://www.wikidata.org/entity/Q36848552

about

Adjuvant therapy for pancreas cancer in an era of value based cancer care Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study.Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival.Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas.Evolving treatment landscape for early and advanced pancreatic cancer.Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients.What treatment in 2017 for inoperable pancreatic cancers?Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

P2860

Q26775916-1FAA0ABD-7E6A-476B-988C-9D060E999B1D Q28072210-21ABF82F-8D66-44F2-ACC5-6F69FE865354 Q28081125-D55BFF35-E30B-4262-B8B3-F1185C851A88 Q36558415-EC98FF82-96C7-4558-ADCA-AA84671AA007 Q37290494-12F5BA6B-9CE9-4226-BE96-159A652F0F7A Q37331861-DBB92063-0E3B-4B05-B89B-EE969AC073E9 Q37555302-74365023-EFA5-4EF1-BC1C-B311721ED47D Q37714700-F71D0376-FA48-4945-8177-38AEABE3B71E Q38624806-9FB14CE7-0F8C-46AB-BB74-42A5ED75A888 Q38674441-D4E4D24F-A546-46A6-ACDE-017417615458 Q38689025-D44242EC-9F8E-41AA-B830-73DA15D53D44 Q38768150-9E9D4BAB-8861-4A7A-8419-A70948C90EB7 Q38829982-01879CD8-45AF-4504-8EF2-143452021EB4 Q38905077-43976AED-ADB2-428B-AA53-DC886BD1C358 Q39023169-D44C9579-70EE-43EE-A2A9-778E9FAD6055 Q39234276-014AC3E4-70D4-4EDF-BF23-BCBF615D8C42 Q40165790-4768289A-3790-4436-91AC-C4DCED61EB6F Q42374126-9D90483D-F58F-481F-9E3A-0E4AAD06430F Q48599351-7126BC59-D6A5-4492-9305-B2AF0F440D1F Q52802886-2287D896-17C5-4018-B16C-906980ABAE6C Q58754830-7087B667-E2A5-4165-AD2D-B6D6700A889E Q58789567-CED4C4E9-E66C-4B31-8028-19402E7C874D Q59137774-279C9482-003A-449E-A9AD-834601D48CDC

P2860

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

http://www.wikidata.org/entity/Q36848552

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

@en

type

label

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

@en

prefLabel

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

@en

P1433

Q36848552-85CB52F9-325D-4112-852C-C8C45975FF72

P1476

Q36848552-66BD8F7A-899A-4793-98D7-551C5E91DB2A

P2093

Q36848552-28125446-3AF1-40B4-8E94-7FFD568B416F

Q36848552-32B386CD-9390-4313-843B-442D71939623

Q36848552-3AC0968B-9E86-487C-80E9-E41ABB563AF7

Q36848552-76F9F34F-4467-4D7A-AA11-D01B3C7EB229

Q36848552-A32E7337-9405-4DE0-A4B6-D2569DA1B78A

Q36848552-B20441A5-5B88-4325-A9E5-4BF727749AB9

Q36848552-BD08812C-4700-4BEE-87D8-4978207D7548

Q36848552-CDC6EB36-9669-41D4-A236-70BCE897017C

Q36848552-E9F58330-E3D1-4D9D-A234-7E9C56E56BCD

P2860

Q36848552-3045CE6E-1E08-49AE-9A10-0FFE7A2E8870

Q36848552-393557B3-8995-4261-B716-3AE04EEB4CDD

Q36848552-41DF14DC-EB9D-4323-89C9-D81F33CE6CAF

Q36848552-48758824-3E6F-4CB6-9087-717DA64E5631

Q36848552-699481DB-9C22-4974-A14C-997E046D2510

Q36848552-6AD46A31-C11D-4585-A8C8-4CBDFF1B1C5F

Q36848552-7188E09E-C2BA-4877-9A2C-C1B8433F575D

Q36848552-833B0C66-94C6-4997-B3EE-32B33517EE8F

Q36848552-9222A5F0-A66F-4147-95C5-FD0C97C2AD48

Q36848552-B11E9981-F224-410F-99BE-36DC64D18B9C

P2888

Q36848552-6E809C48-9B86-4E45-AB09-0FA030D1467E

P304

Q36848552-A6C8C373-E997-44B2-A0BA-84F0151DB072

P31

Q36848552-243A8944-C43A-4067-873A-0C62769650CE

P356

Q36848552-69127DD4-B2E0-4651-968B-04D00714966D

P433

Q36848552-194D2C5B-D20B-463C-9D19-A3D7905CA59E

P478

Q36848552-DCC38E96-B405-4B4F-BA09-E6F2F8198EBF

P50

Q36848552-8DA8C089-BCBC-4A58-A6BB-51C51A1E6EA7

Q36848552-E4D928E2-373B-46C0-A561-0C830958647D

Q36848552-E6C6DE19-E4E6-4F45-A91E-C1B8CDACCFD5

Q36848552-E8638449-E1E0-427E-88E6-8C27E35A8D9A

P577

Q36848552-067AD864-E636-40E6-AFC3-C2FAF195E965

P6179

Q36848552-68ACFB19-7E8A-49FC-A0C0-B281C3784F05

P698

Q36848552-61A9A687-2B78-4D2D-852A-8B56867F5AAD

P921

Q36848552-FE1560F5-A8FB-4539-AEFF-85FA4BAD15FC

P932

Q36848552-735FFDE9-C676-4910-ADDC-B08F5C3EE254

P356

S10434-015-4647-4

P1433

Annals of Surgical Oncology

P1476

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

@en

P2093

Alexandre Doussot

http://www.w3.org/2001/XMLSchema#string

Eran Sadot

http://www.w3.org/2001/XMLSchema#string

Karyn A Goodman

http://www.w3.org/2001/XMLSchema#string

Laura H Tang

http://www.w3.org/2001/XMLSchema#string

Michael I D'Angelica

http://www.w3.org/2001/XMLSchema#string

Mithat Gönen

http://www.w3.org/2001/XMLSchema#string

Peter J Allen

http://www.w3.org/2001/XMLSchema#string

Ronald P DeMatteo

http://www.w3.org/2001/XMLSchema#string

William R Jarnagin

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas.

A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.

Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system.

P2888

s10434-015-4647-4

P304

3512-3521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-015-4647-4

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

T Peter Kingham

Eileen M O'Reilly

P577

2015-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023440883

http://www.w3.org/2001/XMLSchema#string

P698

26065868

http://www.w3.org/2001/XMLSchema#string

P921

P932

4849545

http://www.w3.org/2001/XMLSchema#string